In Brief: Atrovent
Executive Summary
Atrovent: Ipratropium bromide nasal spray available Feb. 1 as a prescription treatment for rhinorrhea associated with perennial rhinitis and for nonallergic reactions and treatment of the common cold. Atrovent was approved Oct. 20 for both indications. The AWP, according to the company, for the 30 mL .03% strength is $33.60 and for 15 mL of the .06% strength is $28.80...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth